Capitalist Countdown: Wealthy VC’s Top 5 Investing News Stories of the Week
Welcome to the Capitalist Countdown by Wealthy VC.
The Capitalist Countdown is a weekly series that features the biggest stories from the market’s hottest stocks as well as news from under-the-radar hidden gems, capable of delivering mutibagger returns to your portfolio.
With that said, please sit back, relax and enjoy the Capitalist Countdown’s top 5 market-moving news stories for the week of November 22nd – 28th, 2021.
5. Elon Musk Follows Through on Twitter Poll, Sells Nearly $7 Billion in Tesla Stock
Love Him or Hate Him, Elon Musk Seems to Follow Through When He Says He’s Going to Do Something, No Matter How Outlandish it May Seem.
Even if that means unloading 10% of his Tesla (NASDAQ: TSLA) (FRA: TL0) holding based on the results of a Twitter (NYSE: TWTR) poll. When the richest man on Earth posted a Twitter poll asking his followers if he should sell 10% of his Tesla shares so he would realize his capital gains and thus be taxed, many people thought it was just another joke. Musk assured the world that he would follow through on his stock liquidation if the public voted for it.
Read the full story here.
4. Pfizer Says Its New COVID Pill Cuts Risks of Hospitalization and Death By 90%
Nearly Two Years Into the COVID-19 Pandemic and After Rigorous Testing, We’re Starting to See Some Game-Changing Medications Being Introduced to Combat the Virus’s Effects
Different from vaccines, which are administered with a shot and provide immunity via antibody development, many of the new COVID therapeutics are now coming in pill form and are designed to treat the virus rather than prevent it. Perhaps the most successful non-vaccine COVID-19 drug has been Pfizer’s (NYSE: PFE) orally administered pill PF-07321332 (working name). Pills are known to be more widely accepted than the injections that vaccines require, so Pfizer has high hopes for its acceptance by the general population. It is expected that Pfizer will market its new COVID pill under the brand name Paxlovid.
Read the full story here.
Also Read: Why Big Investors Who Can’t Buy Crypto Are Gobbling Up These Stocks Instead
3. 4 Social Media Stocks Worth Your Attention Not Named Facebook
As a Subsector of the Tech Sector, the Social Media Industry Offers an Enticing Option for Investors
We took a closer look at and examined these four top Big Tech stocks in the social media industry, not named Facebook (NASDAQ: FB).
Read the full story here.
2. Plant-Based Food Leader Eat Well Group to Expand Investor Base With Listing on National U.S. Stock Exchange
The Plant-Based Food Industry Has Been One of the Hottest Sectors of the Last Few Years
Whether you’re at the grocery store or your favorite restaurant, you’ve likely seen plant-based food products for sale. While big-name plant-based brands like Beyond Meat (NASDAQ: BYND) and Tattooed Chef (NASDAQ: TTCF) are well-known and get plenty of attention, there are other, smaller companies that present investors with even more growth opportunities. Eat Well Group (CSE: EWG) (OTC: EWGFF) (FRA: 6BC0) is one such company. Eat Well is building a vertically integrated plant-based powerhouse with a leading plant-based CPG brand. Since the industry is still relatively new and growing exponentially, it’s ripe for consolidation, as well as huge investor gains.
Read the full story here.
1. After a Breakout Year in 2021, Here’s Why Regeneron Stock Has Even More Upside
For the Millions of Americans Who Have Been Infected With COVID-19, Few Therapeutics Have Been More Effective at Treating the Virus Than Regeneron’s Monoclonal Antibodies Cocktail
Regeneron Pharmaceuticals’ (NYSE: REGN) (FRA: RGO) monoclonal antibodies cocktail REGEN-COV (casirivimab and imdevimab), which received emergency use authorization from the FDA in late 2020, has proven to be an extremely effective therapeutic for treating COVID-19. In fact, a recent study found that REGEN-COV could also be effective at preventing the virus as well, with the study showing that a single dose reduced the risk of contracting COVID-19 by 81.6%. Data from the late-stage trial also indicated that the antibody cocktail has the potential to provide long-lasting immunity from COVID-19 infection of up to eight months.
Read the full story here.
Small Cap News Movers & Winner Deep Dive – By WealthyVC.com
We scan over 10,000 publicly listed stocks across all seven North American exchanges to uncover the market-moving news that actually matters—focusing on high-quality, liquid, growth-oriented companies in sectors attracting serious capital, like AI, blockchain, biotech, and consumer tech.
Each week, we publish Small Cap News Movers, a curated roundup of small and micro-cap stocks surging on meaningful catalysts. We break down what’s driving the move, tap into rumors swirling on social media, and surface sharp insights from both industry experts and retail sleuths.
From this list, we select one standout stock for our Small Cap Winner Deep Dive, released the next day, where we take a closer look at the fundamentals, narrative, and technicals that suggest this winner could keep running.
Powered by our proprietary 4-element, AI-driven analysis system, our goal is simple: cut through the noise, remove the emotion, and help investors dominate the small-cap market with momentum-driven strategies—completely free.
Sign up for email alerts to get the moves before our social media followers.
Read Next: Why Nvidia’s Tech Investments Could Transform the Entire AI Innovation Ecosystem
Join the Discussion in the WVC Facebook Investor Group
Do you have a stock tip or news story suggestion? Please email us at: invest@wealthyvc.com.
Disclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.
